Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (2600)	6/19/1999 3:53:00 PM
From: John Romeo	Read Replies (1) \| Respond to of 4676

I called the company last week and asked IR for copy and updated PR Kit. Have bookmarked your Cancer thread, however can you point me to the gene therapy thread.I had an unbelievably busy week and hadn't kept up with any news,other than market prices,which have been good. Please allow me some time to rest my neurons and I would enjoy discussing the topics you have addresed. Have a Nice Day.

To: Mike McFarland who wrote (2600)	6/20/1999 8:39:00 PM
From: Scott H. Davis	Respond to of 4676

Mike, IMSCO, ISIP will be a lot less niche after they improve their technology sufficiently to provide sufficient bio-availability via systemic administration. The CMV ret med was 1st generation antisense direct injected into an area with reduced outside blood flow. Another test program was scrapped when early results with a 2nd (or was that 3rd) generation version attaching the same indication yielded sufficiently better results that the partner wanted to go full ahead with the 2nd generation. I don't have the credentials you look for, but as a clinical analyst working with Rx and lab for years, I do understand enough pharmacokinetics to see the applicability to larger indications once the tech has progressed sufficiently. Scott And RE VICL, I'd suggest getting their annual report. Good, suscinct info, can be requested free online via the NASDAQ site (and still my favorite biotech balancing long term potertial vs risk)